MedElevator
Войти в исследования Extended-Release Guanfacine Hydrochloride is Safe and Effective as Mono- and Adjunctive Therapy in Children and Adolescents with ADHD: A Naturalistic, Multi-Center, Patient-Reported Outcome Measures-Based Study.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kutuk Meryem Ozlem, Tufan Ali Evren, Kilicaslan Fethiye, Tastepe Neslihan, Imrek Yasemin, Adiguzel Akman Oznur, Alsen Guney Sevay, Baykara Huseyin Burak, Bayraktar Fadime, Akay Pekcanlar Aynur, Korkmaz Gulenay, Ozcan Seda, Ozbaran Nazlı Burcu, Aksu Gülen Guler, Toros Fevziye, Uzun Cakir Aylin Deniz, Cakir Burak, Koksal Merve, Oz Hansa Betul, Kara Aziz, Ozkan Yekta, Celikkol Sadic Cagla, Gercek Hacer Gizem, Polat Tuysuz Berna, Kilic Guder Ayse Nur, Mutlu Caner, Eray Camli Safak, Turan Serkan, Onal Bedia Sultan, Yitik Tonkaz Gulsum, Cobanoglu Osmanli Cansu, Sahin Berkan, Unver Hatice, Tekeoglu Ugur, Naralan Yuksel Sumeyra, Kabukcu Basay Bürge, Basay Omer, Buber Ahmet, Furkan Tanir Muhammed, Gumussoy Ahmet Sefa, Cimen Irem Damla, Yildiz Gundogdu Ozlem, Yildirim Demirdogen Esen, Bozkurt Abdullah, Akinci Mehmet Akif, Buran Burcin Seyda, Ozyurt Gonca, Ozdag Veysel, Sahin Nilfer, Karagoz Duygu, Turan Bahadir, Hosoglu Esra, Korkmaz Ifakat Sule, Gunduz Cilci Yagmur, Esnafoglu Erman, Ikiz Esra Nazli, Subasi Turgut Fatma, Ozturk Masum, Kayis Hakan, Benk Durmus Fatma, Comertoglu Arslan Semiha, Altun Hatice, Ogutlu Hakan, Avcil Sibelnur, Bilgic Berrin, Dincer Mustafa, Gur Kurcaloglu Neslisah, Bozatli Leyla, Aykutlu Hasan Cem, Budagova Gunay, Bilginer Cilem, Cansiz Mehmet Akif, Kandemir Hasan, Gokcen Cem, Inal Neslihan, Ercan Eyup Sabri
Аннотация
METHODS: The study was designed as a naturalistic, Patient-Reported Outcome Measures (PROMs)-based, clinic-based, multi-center study; thirty-two child and adolescent psychiatry clinics from 26 cities located in seven geographical regions of Türkiye were included. Clinicians evaluated ADHD symptom severity at baseline and at the end of the 6th month with Clinical Global Impressions (CGI)-Severity, Improvement, and Adverse Effect scales while parents evaluated symptoms with the DSM-IV-Based Screening Scale for Disruptive Behavior Disorders. Adverse effects after GXR treatment were determined from patient records. Dose equivalents for stimulants, antidepressants, antipsychotics, and mood stabilizers used concurrently with GXR were calculated. Univariate and bivariate analyses along with linear mixed models were used to model change. Logistic regression was used to evaluate predictors of treatment response in sensitivity analysis.
RESULTS: Five hundred and sixty-seven patients (n = 437, 77.1% male) with a mean age of 11.2 (SD = 2.8) years were enrolled. Comorbid diagnoses were common (82.4%) along with combination therapy (85.0%). GXR at a median dose of 2.0 to 3.0 mg/day was associated with improvement and the rate of adverse effects was low. GXR showed differential symptom-domain effects, with greater improvement in hyperactive-impulsive (HI) compared to inattentive (IA) symptoms. Children with comorbid autism spectrum disorder (ASD; n = 175, 30.0% of the sample) showed notable clinical improvement. Response was modified by baseline symptom severity.
CONCLUSION: GXR may be a viable treatment option for children and adolescents with ADHD and various comorbidities among Turkish youth in real-world clinical populations, with baseline symptom severity as a potential modifier of response. The differential response favoring HI symptoms and notable effectiveness in comorbid ASD represent clinically important findings of this naturalistic, PROM-based study.